Wed.Apr 10, 2024

article thumbnail

STAT+: Cancer vaccines gain momentum, after years of disappointing results

STAT

SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner. “There’s a lot more interest in vaccines” now that the technology is improving, said Roy Herbst, chief of medical oncology at Yale Can

Vaccines 363
article thumbnail

Psychiatry drugs finally have pharma’s attention. Can they keep it?

PharmaVoice

Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

240
240
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Drug shortages reached a record high as 2023 drew to a close

STAT

The number of ongoing and active drug shortages in the U.S. stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. Unresolved shortages have, in fact, been hovering above 300 for more than a year as numerous basic and life-saving medicines are in short supply.

article thumbnail

What’s old is new: The revival of a one-time radiotherapy cancer treatment

PharmaVoice

TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.

299
299
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Vertex to buy Alpine Immune Sciences for $4.9 billion

STAT

Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest acquisition in Vertex’s history. The acquisition gives Vertex a drug called povetacicept, which has shown promise in treating IgA nephropathy (IgAN), an autoimmune disorder of the kidney that can lead to end-stage renal disease and affects 130,000 people in the U.S.

article thumbnail

New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way.

BioPharma Dive

The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.

126
126

More Trending

article thumbnail

Novartis pauses some trials of cancer drug Kisqali to fix manufacturing

BioPharma Dive

The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

114
114
article thumbnail

STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified

STAT

In an era when huge price hikes for prescription drugs are almost guaranteed to draw criticism, is there any circumstance when a 486% increase for a medicine might appear to be justified? A small company called Harrow argues that it can make the case for an injectable eye treatment that has been used to combat several serious conditions. Company executives maintain the medication, which has been largely out of stock for the past few years, requires substantial investment in order to restore a st

article thumbnail

Sunshine transparency reporting for emerging pharma: Simplify, streamline, and secure

pharmaphorum

Discover how Sunshine transparency reporting can be simplified, streamlined, and secured for emerging pharmaceutical companies with a focus on Healthcare Professionals (HCP) and Healthcare Organisations (HCO).

article thumbnail

Opinion: Cancer is a killer. So is the fear of it

STAT

The widespread attention to the recent revelations of cancer diagnoses by Princess Catherine , actress Olivia Munn , and King Charles , among others, demonstrate yet again that cancer is a feared disease. For good reason: It is a cruel killer, the second leading cause of death in the U.S. and a top killer around the world. So public faith in cancer screening (checking seeming healthy people for signs of hidden disease) is deep, driven by the widespread understanding that finding cancer early &#x

313
313
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Vertex to buy kidney disease drugmaker Alpine for $4.9B

BioPharma Dive

The deal, which company CEO Reshma Kewalramani described as “just the right fit,” is the largest acquistion in Vertex’s 35-year history.

122
122
article thumbnail

STAT+: BIO’s top lobbyist exits, signaling reorganization

STAT

WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist, the group confirmed to STAT, adding to a recent bout of organizational tumult. The departure of Nick Shipley may be part of a greater shake-up spearheaded by the Biotechnology Innovation Organization’s new CEO, John Crowley, who took over in December.

315
315
article thumbnail

UK calls time-out on post-Brexit rules opposed by industry

pharmaphorum

The UK has agreed to delay border checks on products used in life sciences R&D and manufacturing, says industry group BIA.

130
130
article thumbnail

STAT+: Regeneron accused by Justice Department of manipulating Medicare pricing

STAT

The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing by inflating the average sales price for its expensive and widely prescribed Eylea treatment for serious eye disease. In its lawsuit, the Justice Department claimed the company failed for more than a decade to report how it paid “hundreds of millions of dollars” to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

How Efficient Logistics Can Change the Lives of Rare Disease Patients

Pharmaceutical Commerce

If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.

105
105
article thumbnail

Opinion: Mental health screening tools for kids are 30 years out of date

STAT

Suicide is the second leading cause of death among children aged 10 to 14 in the U.S. That’s evidence of a systemic failure in identifying and addressing mental health concerns in young people. Compounding the problem is the average delay of 11 years between the onset of a mental health condition and its diagnosis. Think about it: a child exhibiting signs of mental health challenges at age 6 may not receive proper diagnosis or treatment until age 17.

article thumbnail

Dr Reddy’s launches drug-free migraine management device Nerivio in Europe

Express Pharma

Dr Reddy’s Laboratories announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company’s entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

105
105
article thumbnail

STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

AACR: BTK degrader could treat CNS B-cell malignancies

European Pharmaceutical Review

First evidence of clinical activity in the brain for a targeted protein degrader has been demonstrated with NX-5948, an orally available, selective degrader of Bruton’s tyrosine kinase (BTK). The small molecule anti-cancer treatment from Nurix Therapeutics is currently being investigated in a Phase I clinical trial in patients with relapsed or refractory B cell malignancies.

article thumbnail

AskBio CSO steps down, has new project in stealth mode

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello! Today, we get some optimism from the new director of the National Cancer Institute, despite a brain drain playing out in the industry and stagnant funding numbers. Also, advocates press the federal government to encourage manufacturing for the prostate cancer drug Xtandi.

article thumbnail

Bio-Rad and Alleghany Health Network partner for patients with solid tumour cancer

Pharma Times

Solid tumour cancers account for 90% of adult human cancers and 50% of childhood malignancies

129
129
article thumbnail

Unique testing regimen could prevent nuclease contamination

European Pharmaceutical Review

A novel routine nuclease testing regimen developed to ensure resilience against nuclease contamination can be utilised as part a laboratory’s quality management system (QMS), a paper reports. The regimen may be applied as a quality indicator fulfilling certain ISO quality control criteria, and offers “documented, systematic feedback”. Cleavable, fluorescent DNA and RNA substrates were used to detect, monitor and control for nuclease contamination in the laboratory, according to the authors.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

‘Clarity needed’ on dispensing privately prescribed puberty suppressing hormones

The Pharmacist

Government and regulators must ‘clearly communicate’ the extent of community pharmacists’ responsibilities when asked to dispense privately prescribed puberty suppressing hormones to children and young people, an independent review has said. The final report of the Cass review, published today, called for measures to reduce inappropriate overseas prescribing of puberty suppressing hormones.

article thumbnail

Women in Science: Elisa Cascade on why women should never be afraid to ask

Outsourcing Pharma

Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome, how to avoid suffering in silence and her 'just do it' mantra.

99
article thumbnail

Essential adds neuroblastoma drug with Renaissance buy

pharmaphorum

Essential Pharma has bought Renaissance Pharma, adding its first developmental drug candidate, a therapy for rare cancer neuroblastoma.

115
115
article thumbnail

CRISPR-based innovations drive $21 bn in pharma licensing deals over five years: GlobalData

Express Pharma

The pharma industry has experienced a notable uptick in licensing agreements for innovator drugs incorporating c lustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years. These agreements, primarily concentrated in oncology, immunology, and central nervous system therapeutics, have collectively accumulated an impressive $21 billion in deal value.

96
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Vertex wagers $4.9bn on Alpine kidney disease therapy

pharmaphorum

In another departure from its focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA nephropathy (IgAN). The $65-per-share deal is due to close within the next three months, said Vertex, which plans to fund the acquisition with cash in hand. It is the largest acquisition in the biopharma sector so far in 2024.

article thumbnail

Advancing microbiome innovation

European Pharmaceutical Review

Over the past decade, there has been an increase in discussions involving industry stakeholders, regulatory agencies, and physicians about developments in the emerging microbiome therapeutics industry. The field initially triggered inquiries and these conversations have since evolved, indicating a noticeable positive shift in attitudes over time. The recent FDA approvals of two microbiome products in the US, in November 2022 and April 2023, 1-2 represent a significant milestone, maturing the i

article thumbnail

Independent experts recruited to UK pharmacy leadership board

The Pharmacist

Nine independent expert members (IEMs) have been appointed to the UK Pharmacy Professional Leadership Advisory Board. The UK-wide advisory board was set up last year with the aim of supporting and enabling collaborative working between organisations representing pharmacists and pharmacy technicians in different settings. The four UK chief pharmaceutical officers (CPhOs) then embarked on a […] The post Independent experts recruited to UK pharmacy leadership board appeared first on The Pharm

article thumbnail

e-therapeutics is latest UK biotech to seek AIM de-listing

pharmaphorum

e-therapeutics is the latest UK biotech to say it plans to delist from the AIM, citing a lack of interest from institutional investors.

104
104
article thumbnail

Study reveals shorter scans for prostate cancer could improve diagnosis

Pharma Times

The most common form of cancer in men is responsible for 12,000 deaths every year in the UK

Hospitals 108